These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27337801)

  • 21. Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
    Duan H; Lu J; Lu T; Gao J; Zhang J; Xu Y; Wang M; Wu H; Liang Z; Liu T
    Int J Clin Exp Pathol; 2015; 8(10):13136-45. PubMed ID: 26722512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.
    Hu W; Yang Y; Zhang L; Yin J; Huang J; Huang L; Gu H; Jiang G; Fang J
    Cancer Med; 2017 May; 6(5):962-974. PubMed ID: 28382702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
    Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
    Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
    Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
    Oncotarget; 2015 May; 6(14):12809-21. PubMed ID: 25980577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
    Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
    Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
    J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
    Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
    Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
    Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
    Zhao X; Han RB; Zhao J; Wang J; Yang F; Zhong W; Zhang L; Li LY; Wang MZ
    Respiration; 2013; 85(2):119-25. PubMed ID: 22797485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a fast and fully automated platform to diagnose
    Lambros L; Caumont C; Guibourg B; Barel F; Quintin-Roué I; Marcorelles P; Merlio JP; Uguen A
    J Clin Pathol; 2017 Jun; 70(6):544-549. PubMed ID: 28153953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.
    Danese E; Minicozzi AM; Benati M; Montagnana M; Paviati E; Salvagno GL; Lima-Oliveira G; Gusella M; Pasini F; Lippi G; Guidi GC
    PLoS One; 2015; 10(5):e0126417. PubMed ID: 25946211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
    Hu Y; Ulrich BC; Supplee J; Kuang Y; Lizotte PH; Feeney NB; Guibert NM; Awad MM; Wong KK; Jänne PA; Paweletz CP; Oxnard GR
    Clin Cancer Res; 2018 Sep; 24(18):4437-4443. PubMed ID: 29567812
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
    Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
    Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
    Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
    Lee SM; Bae SK; Jung SJ; Kim CK
    Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.